<p fr-original-style="" style="margin-top: 0px; margin-bottom: 1em; box-sizing: border-box;">• <a fr-original-style="" href="https://www.ft.com/content/45dc4b67-f4a5-4fac-8c35-1d63b823c065" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank"><strong fr-original-style="" style="font-weight: 700; box-sizing: border-box;">GSK’s consumer health spin-off Haleon</strong></a> became the largest London listing in more than a decade on its first day of trading, making it the world’s biggest standalone consumer health business. Haleon shares opened at 330p (€3.88), giving the group a market valuation of £30.5 billion (€36bn), the biggest London listing since Glencore’s £37 billion (€43.7bn) IPO in 2011.</p>

spin-off ile ilgili hikayeler